2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|November 2, 2004
- Pharmaceutical Technology-11-02-2004
- Volume 28
- Issue 11
Bringing Formulations to Size: Strategies for Micro- and Nanoparticle Development
With creative engineering and sophisticated chemistry, industry scientists offer big solutions for attaining small particle sizes and narrow distributions.
Advertisement
Articles in this issue
almost 22 years ago
Still Waiting for Answersalmost 22 years ago
Method Validation by Phase of Development: An Acceptable Analytical Practicealmost 22 years ago
Comparing and Contrasting Barrier Isolator Decontamination Systemsalmost 22 years ago
November 2004almost 22 years ago
In the Spotlight-November 2004almost 22 years ago
Searching for a Viable Business Modelalmost 22 years ago
FDA Moves To Implement New GMP PoliciesAdvertisement
Related to this article
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
PharmTech AI Pulse Check: Fixing AI Slop at the Source
3
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
4
Introducing the "PharmTech AI Pulse Check" Expert Video Series
5